Microvascular Therapeutics’ Post

Fund-Raised Global Digital Therapeutics (DTx) Startups - Investors Mapping Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis regarding their fundraising status. Among these, 94 Digital Therapeutics (DTx) startups have collectively raised $6.859 billion from global investors. These startups include Raft Digital Therapeutics, Mindable Health GmbH, MicroHealth, Vigo Health, SleepUp, Vitadio s.r.o., Neurolief, OPTT Health, Vivira Health, XR Therapeutics, and many others. They are supported by a diverse range of investors, such as aMoon Fund, Expansion Capital, UV-Cap, 7wireVentures, Accelmed Partners, Adage Capital Management, and BCG Digital Ventures, among others. This substantial funding highlights the growing investor confidence and interest in DTx innovations. #dtx #digitaltherapeutics #startup #vc #funding #fundraising #investment

Two years ago, GHIC and Biomedical Advanced Research and Development Authority (BARDA) Ventures embarked on a 10-Year public-private partnership to accelerate the development of #MedicalCountermeasures that address gaps in #GlobalHealthSecurity. With BARDA Ventures funding and support, GHIC has invested in 12 biotechnology companies that address gaps in public health response capabilities. Building upon the early progress of the partnership, BARDA has awarded GHIC an additional $152 million, including a $100 million ProjectNext Gen award, to expand the pipeline of venture capital investments in next-generation #vaccines, #therapeutics, #biomanufacturing and other medical countermeasures to bolster public health preparedness and rapidly respond to health security threats and future pandemics. Read more about the second year of partnership and recent $100 million Project NextGen award. https://lnkd.in/e4wwxYwT https://lnkd.in/eSkChv9q

As a biotech CEO, understanding your global partnering options is more important than ever. The fundraising environment remains complicated as you can read from the article below. Partnering can give you additional financial runway, bring credibility to your pipeline, and differentiate you from your peers. KYBORA has great relationships with strategics and investors located all over the world. Please reach out to discuss your current situation. #biotech #fundraising #licensing #extendingyourraunway #success

Some good news in the Biotech VC funding landscape, Regeneron is launching a 500M VC fund Regeneron Ventures 👀 The fund will be "agnostic to therapeutic area, technology and stage of development." Looking forward to seeing what comes from this and hopefully more capital continues to enter the early-stage biotech space. 📈 #Funding #Biotech #VentureCapital

#Stockholm-based #HadeanVentures Secures Hadean Capital II, at EUR 144M. The fund will invest in life science start-up companies across #Europe with an emphasis on the Nordics and German-speaking countries. The strategy includes pharma, biotech, medtech, diagnostics and digital health. Hadean Capital II was launched in September 2021 and has so far #invested in six companies including Alex Therapeutics, Arthex Biotech, Complement Therapeutics, Emergence Therapeutics, Ribbon Biolabs and TargED. The first exit was already successfully achieved with the #acquisition of Emergence Therapeutics by Eli Lilly. Hadean Ventures is a #leading European life science fund #manager with approx. EUR 230m assets under management. The funds are backed by leading private and institutional European and US-based #investors. Hadean Ventures ARTHEx Biotech Johan Bøe Bjørkevoll Magnus Skåninger Walter Stockinger, Dr Ingrid Teigland Akay, MD MBA To share your startup story write us on - contact@startuprise.co.uk #hedeanventure #funding #eustartup

The VentureCap Insights Newsletter (21 Sept 2023) - covering latest updates on fundraising, valuations, and revenue for startups raising or filing financials. Click below to read the full newsletter. You can also subscribe to the daily VentureCap Insights newsletter: https://lnkd.in/g_PfACy If you are a platform that would like to connect with a Startup or a VC, drop us an email at support@venturecapinsights.com and we can help you get that coverage, with our newsletters going out to nearly 30,000 readers - consisting of mostly startups and investors. #VentureCapInsights #Startups #Investors #VentureCapital #PrivateEquity #FinancialData

Investors for Global Digital Therapeutics (DTx) Startups  Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis regarding their fundraising status. Among these, 94 Digital Therapeutics (DTx) startups have collectively raised $6.859 billion from global investors. These startups include Raft Digital Therapeutics, Mindable Health GmbH, MicroHealth, Vigo Health, SleepUp, Vitadio s.r.o., Neurolief, OPTT Health, Vivira Health, XR Therapeutics, and many others. They are supported by a diverse range of investors, such as aMoon Fund, Expansion Capital, UV-Cap, 7wireVentures, Accelmed Partners, Adage Capital Management, and BCG Digital Ventures, among others. This substantial funding highlights the growing investor confidence and interest in DTx innovations. #dtx #digitaltherapeutics #startup #vc #funding #fundraising #investment

A new VC fund emerges with $310M to create independent, commercial biotechs! 💡 💊 Who?? - Aaron Kantoff - Sam Hall - Tadd Wessel   💊 𝗪𝗵𝗮𝘁??  - Scion Life Sciences on Wednesday made its debut as a venture firm, announcing the close of a $310 million fund to invest in new biotechnology startups. - Led by a trio of biotech veterans with experience at firms like Apple Tree Partners and Medicxi, Scion plans to focus initially on backing a half-dozen life sciences companies. - In addition to offering entrepreneurs funding, Scion plans to manage some research and development capabilities as well as provide operational support. 💊 𝗪𝗵𝘆??   - Scion is pitching a model that shares similarities with an approach startup creators like Flagship Pioneering and Arch Venture Partners have had success with. - The new firm aims to build a small number of "durable" startups equipped with significant resources and funding — a notable emphasis after the past two years saw many young drugmakers struggle to survive.   ❓ 𝑫𝒊𝒅 𝒚𝒐𝒖 𝒌𝒏𝒐𝒘... They don’t plan to build biotechs with the goal of quickly selling them to pharmaceutical buyers. Though M&A is a key piece of the biotech ecosystem, Scion wants its companies to be able to independently commercialise their drugs if they don’t end up partnering with a larger firm. This is going to be an exciting time for biotechs across the globe!! #VC #Investment #pharma #biotech

#fundingalert 💼Company: Remepy 💰Funding: $10Million ⚡Round: Seed 👥Investors: TechAviv, Fresh.fund, Samsung Next, StageNext Fund, 97212 Ventures, NFX, Vine Ventures, PsyMed Ventures, Supernode Ventures, and Firstime VC Remepy is a Leader in Hybrid PharmaceuticalsTM. They think that in the future, software programmes will be a crucial component of the therapies that pharmaceutical firms provide as Hybrid DrugsTM. Remepy is at the forefront of the development of hybrid pharmaceuticals, which mix traditional medications with personalised digital therapy to improve the efficacy of pharmacological treatments. The company is led by Michal Tsur and Or Shoval. Shahar Shelly M.D, Johnathan Amit Kanarek, Ofer Tur-Sinai, Shai Erlich, Lior Benderski Read more -https://lnkd.in/gSKWPSHn To share your startup story write us on - contact@startuprise.io #Remepy #HybridPharmaceuticals #development #software #pharmacological #funding #fundingnews #news #startupnews #startup #startuprise

The VentureCap Insights Newsletter (14 Sept 2023) - covering latest updates on fundraising, valuations, and revenue for startups raising or filing financials. Click below to read the full newsletter. You can also subscribe to the daily VentureCap Insights newsletter: https://lnkd.in/g_PfACy If you are a platform that would like to connect with a Startup or a VC, drop us an email at support@venturecapinsights.com and we can help you get that coverage, with our newsletters going out to nearly 30,000 readers - consisting of mostly startups and investors. #VentureCapInsights #Startups #Investors #VentureCapital #PrivateEquity #FinancialData